26.10.2022 09:00:00
|
83,587 Orion Corporation A shares converted into B shares
ORION CORPORATION
STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
26 OCTOBER 2022 at 10.00 EEST
83,587 Orion Corporation A shares converted into B shares
In accordance with Section 3 of the Articles of Association of Orion Corporation, 83,587 A shares have been converted into 83,587 B shares. The conversion has been entered into the Trade Register on 26 October 2022.
The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,226,937 A shares and 106,907,341 B shares. The number of votes of the company's shares is after the conversion 791,446,081.
Orion Corporation
Jari Karlson CFO | Olli Huotari SVP, Corporate Functions |
Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.


Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Orion Corporation (New) (B)mehr Nachrichten
24.02.25 |
Ausblick: Orion B legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) | |
10.02.25 |
Erste Schätzungen: Orion B mit Zahlen zum abgelaufenen Quartal (finanzen.net) | |
15.01.25 |
Inside information: Orion upgrades full-year outlook for 2024 and provides preliminary information on financial performance for 2024 (GlobeNewswire) | |
24.10.24 |
Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule (GlobeNewswire) | |
14.10.24 |
Erste Schätzungen: Orion B informiert über die jüngsten Quartalsergebnisse (finanzen.net) |
Analysen zu Orion Corporation (New) (B)mehr Analysen
Aktien in diesem Artikel
Orion Corporation (New) (B) | 54,04 | 0,71% |
|